Back to results
US 12,472,218 B2Granted
Seneca valley virus (SVV) cellular receptor targeted oncotherapy
AssigneeMemorial Sloan Kettering Cancer Center
InventorsLinde Miles, John Poirier, Charles Rudin
Life of this patent
Estimating the term…
Abstract
A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
Claims4
A kit for selecting a cancer patient for treatment with a Seneca Valley Virus (SVV), a SVV mutant or a SVV variant, comprising:
- (1) reagents for detecting an expression level of anthrax toxin receptor 1 (ANTXR1);
- (2) a reagent for detecting expression levels of one or more biomarkers of the α-interferon or β-interferon pathway;
- and
- (3) instructions to select a cancer patient for treatment with a Seneca Valley Virus (SVV), a SVV mutant or a SVV variant when a subject is identified as having a cancerous tissue with a normal expression level or an elevated expression level of ANTXR1 and a decreased expression level of a biomarker of the α-interferon or β-interferon pathway.
1 more element
Dependencies are inferred from the claim text.